Younger Patients with History of Skin Cancer who Smoke More Likely to Develop Extra-Cutaneous Cancers
the Cancer Therapy Advisor take:
In a study published online ahead of print in the Journal of the European Academy of Dermatology and Venereology, researchers sought to determine whether a history of nonmelanoma skin cancer (NMSC) and/or melanoma is associated with extracutaneous cancers.
Data from 447,801 adult participants in the 1997-2011 National Health Interview Survey was assessed, including their history of NMSC, melanoma and 27 extracutaneous cancers. They found that NMSC was associated with a higher risk for one or more extracutaneous malignancies, as was a history of melanoma.
Extracutaneous cancers were found more often in younger patients and Caucasian patients with NMSC or melanoma. In addition, they researchers found that smokers with a history of NMSC or melanoma that were between the ages of 18 and 39 had even higher risk of developing an extracutaneous malignancy.
Patients with a history of NMSC were more likely to develop cancers of the bladder, brain, breast, colon, esophagus, kidney, lung, lymphoma, melanoma, prostate, soft tissue, throat/pharynx, thyroid and uterus, while those with melanoma were more likely to develop bladder, breast, colon, kidney, lung, pancreas, prostate, soft tissue, throat/pharynx, thyroid and uterus cancers.
History of nonmelanoma skin cancer and/or melanoma is associated with extracutaneous cancers established.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma
- PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer
- Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances